Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    BusinessNewsAsia.comBusinessNewsAsia.com
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    BusinessNewsAsia.comBusinessNewsAsia.com
    Home»BioTech»Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence
    BioTech

    Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence

    Marie JonesBy Marie JonesJuly 29, 2025No Comments3 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Biolog, a leading provider of microbial identification and phenotypic characterization tools and services, announced today that both its anaerobic media and anaerobic chambers have received CE marking, clearing the way for broader international use

    Biolog, a leading provider of microbial identification and phenotypic characterization tools and services, announced today that both its anaerobic media and anaerobic chambers have received CE marking, clearing the way for broader international use. The media and chambers were part of Biolog’s acquisition of Anaerobe Systems earlier this year with the objective of bringing class-leading tools for microbiology to the rapidly growing clinical, microbiome, and agricultural markets.

    Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture ExcellenceToday, Biolog’s TruPRASā„¢ media is the only commercial media manufactured under true pre-reduced, anaerobically sterilized conditions, preventing the formation of harmful byproducts that can be toxic to anaerobic organisms. This line of media products, which has been approved for In Vitro Diagnostic (IVD) use by the USA FDA for years, has now also achieved CE marking under the requirements of the EU IVDR regulation 2017/746. With zero recalls or field actions throughout their extensive history, these products enable transport of specimens and growth of fastidious anaerobes that play important roles in disease pathology – supporting clinical diagnostics in medical laboratories.

    “The IVDR/CE mark is a major milestone that recognizes the high standard of our anaerobic media and its value in supporting critical diagnostic workflows,” said Robert Wicke, CEO at Biolog. “We’re proud that clinical labs throughout Europe can now benefit from the same reliable performance that researchers and clinicians in the U.S. have trusted for decades.”

    Biolog’s anaerobic chambers have also received the CE mark, affirming their safety and performance for use in any research settings throughout the world. With unique InstaSleeveā„¢ technology, these ergonomic, gloveless chambers offer superior processing dexterity while working in a fully anaerobic environment and are a preferred tool for microbiologists in both clinical and academic settings. In addition, Biolog is releasing an upgrade to enable hypoxic or microaerophilic conditions in the same chamber, for organisms that require specific, low concentrations of oxygen to thrive.

    “This dual achievement reinforces Biolog’s commitment to advancing global access to high-quality tools for anaerobic microbiology,” said Wicke. “Whether you’re working with challenging clinical isolates or conducting fundamental research, Biolog now provides dependable CE-marked solutions that meet your needs.”

    About Biolog
    Biolog offers tools, services, and support for comprehensive cellular characterization and multi-omic identification of bacteria, yeast, and fungi. Our products also enable phenotypic profiling of microbial and mammalian cells for a range of applications, including supporting the culture of fastidious anaerobes with our line of gloveless chambers and pre-reduced media. Learn more at biolog.com

    Contact Information
    John Proctor, Ph.D.
    CCO
    jproctor@biolog.com
    (408)306-0414.

    SOURCE: Biolog, Inc.

    Biolog Inc
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleGEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer’s and Other Neurodegenerative Diseases
    Next Article Ongoing Share Buybacks Demonstrate Confidence, Shoucheng Holdings Boosts Market Expectations with Concrete Action

    Related Posts

    Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

    June 4, 2026

    Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence

    May 15, 2026

    Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair concluded successfully

    May 13, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.